Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

By NASDAQ10 days ago

AD

Harpoon Therapeutics, Inc. HARP announced that the FDA has granted Orphan Drug designation toHPN217 for the treatment of multiple myeloma.

Continue read on nasdaq.com